Drug intelligence / Profile preview

lificiguat

Development stage: Preclinical
Lead developer: National Taiwan University
Modality: Small Molecules
Administration: Oral, Intraperitoneal

Overview

Lificiguat (YC-1) is a small molecule and synthetic indazole derivative that acts as a nitric oxide-independent activator of soluble guanylate cyclase (sGC). It significantly elevates intracellular cGMP levels, induces vasodilation, inhibits platelet aggregation, and has demonstrated antiproliferative effects in cancer models by inducing G1 cell cycle arrest and inhibiting hypoxia-inducible factor 1-alpha (HIF-1α) activity. It is used primarily as a pharmacological tool in research and is not approved for clinical use in humans.

Other names: lificiguat3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole[5-(1-benzylindazol-3-yl)furan-2-yl]methanol(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanolYC1YC-1YC 1

Targets

HIF1A (Hypoxia-inducible factor 1-alpha)sGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on lificiguat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lificiguat.

Explore the full profile